Status:
COMPLETED
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
Lead Sponsor:
University Hospital Southampton NHS Foundation Trust
Conditions:
Classical Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This prospective observational study aims to evaluate the robustness and persistence of immune responses to vaccination, define factors associated with impaired immune responses and assess the inciden...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA
- Patients having a confirmed diagnosis of either:
- A) Hodgkin lymphoma B) Aggressive B-cell lymphoma (e.g. Burkitt's lymphoma, diffuse large B-cell lymphoma, grade 3b follicular lymphoma, de novo transformed follicular lymphoma) C) Indolent B-cell lymphoma (e.g. all grades of follicular lymphoma except grade 3b, marginal zone lymphoma, lymphoplasmacytic lymphoma, chronic or small lymphocytic lymphoma, mantle cell lymphoma) D) Mature T/NK-cell malignancy (any subtype)
- Patient must be ≥ 18 years.
- Patients will have provided written Informed Consent.
- EXCLUSION CRITERIA
- 1\) Serious medical or psychiatric illness likely to affect participation or that may compromise the ability to give informed consent.
Exclusion
Key Trial Info
Start Date :
March 11 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2024
Estimated Enrollment :
592 Patients enrolled
Trial Details
Trial ID
NCT04858568
Start Date
March 11 2021
End Date
January 31 2024
Last Update
February 6 2024
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Bedfordshire Hospitals NHS Foundation Trust
Bedford, Bedfordshire, United Kingdom, MK42 9DJ
2
Portsmouth Hospitals University NHS Trust
Portsmouth, Hampshire, United Kingdom, PO6 3LY
3
University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, United Kingdom, SO16 6YD
4
Wye Valley NHS Trust
Hereford, Herefordshire, United Kingdom, HR1 2ER